STOCK TITAN

INSM insider filing shows $26.9M proposed sale; prior $5.19M sold

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filed for Insmed, Inc. (INSM) reporting a proposed sale of common stock. The notice lists a proposed sale of 186,648 shares through Merrill Lynch (Washington, DC) with an aggregate market value of $26,935,498 and total shares outstanding of 211,374,786. The shares to be sold were acquired on 09/02/2025 under a stock plan and the payment/settlement date is the same day. The filing also discloses that the reporting person, Martina Flammer, sold 55,564 shares during the past three months for aggregate gross proceeds of $5,190,291 across four transactions dated 06/03/2025 to 08/04/2025. The form includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

  • None.

Negative

  • Large proposed insider sale: 186,648 shares with an aggregate market value of $26,935,498 may increase available float and could be viewed negatively by some investors
  • Recent selling activity: The reporting person sold 55,564 shares in the prior three months for $5,190,291, indicating sustained dispositions

Insights

TL;DR: Insider selling is significant in size but appears executed under a stock plan; market impact depends on context.

The filing shows a proposed block sale of 186,648 common shares valued at $26.9 million, plus 55,564 shares sold in the prior three months for $5.19 million. For a company with 211.4 million shares outstanding, the proposed sale represents ~0.09% of outstanding shares, which is notable for an individual insider but not necessarily market-moving on its own. The transfer is documented as stock plan activity, indicating these are plan-originated shares rather than third-party disposition or litigation-driven sales. The size and recent cadence of sales are material to liquidity and dilution considerations and warrant monitoring alongside trading volumes.

TL;DR: Routine insider disposition under a stock plan with required certification; no disclosed material nonpublic information.

The filer certified lack of undisclosed material adverse information and referenced a stock plan acquisition dated the same day as the proposed sale. That suggests compliance with Rule 144 procedural requirements and possible pre-established plan mechanics. The repeated disposals by the same person over recent months could reflect scheduled vesting or planned diversification. The form does not state adoption of a Rule 10b5-1 plan or the plan adoption date, so it is unclear whether these sales follow an affirmative pre-clearance schedule; that absence limits conclusions about intent or governance safeguards.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for INSM disclose?

The form discloses a proposed sale of 186,648 common shares via Merrill Lynch with an aggregate market value of $26,935,498 and prior three-month sales of 55,564 shares totaling $5,190,291.

Who is the seller named in the filing?

The filing identifies Martina Flammer as the person who sold shares in the prior three months and is the subject of the proposed sale notice.

When were the shares to be sold acquired?

The shares listed for proposed sale were acquired on 09/02/2025 and the acquisition is described as Stock Plan Activity.

How many shares does INSM have outstanding per the filing?

The filing reports 211,374,786 shares outstanding.

Does the filing state whether there is undisclosed material information?

The signer represents by signing the notice that they do not know of any material adverse information about the issuer that has not been publicly disclosed.
Insmed Inc

NASDAQ:INSM

INSM Rankings

INSM Latest News

INSM Latest SEC Filings

INSM Stock Data

34.34B
211.09M
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER